Sangamo Therapeutics Inc (NASDAQ:SGMO) shares traded -3.67% lower at $0.58 on Wall Street last session.
In accordance with the data, 11 analysts cover Sangamo Therapeutics Inc (NASDAQ:SGMO). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $1.50, we find $6.00. Given the previous closing price of $0.60, this indicates a potential upside of 900.0 percent. SGMO stock price is now -43.71% away from the 50-day moving average and -69.28% away from the 200-day moving average. The market capitalization of the company currently stands at $102.25M.
It has been rated a hold by 2 analysts and a buy by 7. Brokers who have rated the stock have averaged $6.01 as their price target over the next twelve months.
With the price target reduced from $5 to $1.50, BofA Securities Downgraded its rating from Neutral to Underperform for Sangamo Therapeutics Inc (NASDAQ: SGMO).
In other news, BIOGEN INC., 10% Owner sold 6,000,000 shares of the company’s stock on Sep 26. The stock was sold for $3,000,000 at an average price of $0.50. Upon completion of the transaction, the 10% Owner now directly owns 17,652,466 shares in the company, valued at $10.24 million. Insiders disposed of 145,492 shares of company stock worth roughly $84385.36 over the past 1 year. A total of 14.13% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SGMO stock. A new stake in Sangamo Therapeutics Inc shares was purchased by GLOBEFLEX CAPITAL L P during the first quarter worth $403,000. JANE STREET GROUP, LLC invested $384,000 in shares of SGMO during the first quarter. In the first quarter, AXA S.A. acquired a new stake in Sangamo Therapeutics Inc valued at approximately $265,000. PUTNAM INVESTMENTS LLC acquired a new stake in SGMO for approximately $206,000. POINT72 MIDDLE EAST FZE purchased a new stake in SGMO valued at around $63,000 in the second quarter. In total, there are 255 active investors with 60.12% ownership of the company’s stock.
Sangamo Therapeutics Inc (NASDAQ: SGMO) opened at $0.6010 on Thursday. During the past 12 months, Sangamo Therapeutics Inc has had a low of $0.60 and a high of $5.27. As of last week, the company has a debt-to-equity ratio of 0.16, a current ratio of 2.97, and a quick ratio of 2.97. The fifty day moving average price for SGMO is $1.0258 and a two-hundred day moving average price translates $1.8791 for the stock.
The latest earnings results from Sangamo Therapeutics Inc (NASDAQ: SGMO) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.66, missing analysts’ expectations of -$0.34 by -0.32. This compares to -$0.29 EPS in the same period last year. The net profit margin was -90.85% and return on equity was -71.93% for SGMO. The company reported revenue of $6.83 million for the quarter, compared to $29.38 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -76.73 percent. For the current quarter, analysts expect SGMO to generate $9.36M in revenue.
Sangamo Therapeutics Inc(SGMO) Company Profile
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
